Adaptive Biotechnologies reported a breakout 2025: total revenue rose 55% to $277 million, driven by 46% growth in its...

Ocular Therapeutix has granted inducement equity awards to five newly hired non-executive employees, including options to purchase 13,850 shares...

XORTX Therapeutics has extended the deadline to close its acquisition of Vectus Biosystems’ renal anti‑fibrotic program, including the novel...

Syndax Pharmaceuticals will spotlight its strategy at the 2026 Guggenheim Emerging Outlook: Biotech Summit on February 12, with a...

Rhythm Pharmaceuticals will put its finance chief on stage next week. The company’s CFO is scheduled for a fireside...

INVO Fertility has outlined its strongest operating stance to date, pointing to clinic-level profitability across three sites, a pending...

Novartis closed 2025 with net sales of $54.5 billion, up 8% in constant currencies, core operating income up 14%,...

The global life sciences sector is currently navigating a significant transition in capital market dynamics, shifting from a period...

NMD Pharma reported topline Phase 2a results from SYNAPSE-CMT, a randomized, double-blind, placebo-controlled study of ignaseclant, its first-in-class skeletal...

NMD Pharma reported topline Phase 2a results for ignaseclant in Charcot-Marie-Tooth disease (CMT) types 1 and 2. The randomized,...